Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

BACKGROUND: Palonosetron (Aloxi®, Onicit®) is a pharmacologically unique 5-HT(3) receptor antagonist (RA) approved as a single IV injection for the prevention of nausea and vomiting induced by chemotherapy (CINV) of either moderate or highly emetogenic potential (MEC and HEC, respectively). An oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Boccia, Ralph, Grunberg, Steven, Franco-Gonzales, Edwin, Rubenstein, Edward, Voisin, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612585/
https://www.ncbi.nlm.nih.gov/pubmed/23354552
http://dx.doi.org/10.1007/s00520-012-1691-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612585/
https://www.ncbi.nlm.nih.gov/pubmed/23354552
http://dx.doi.org/10.1007/s00520-012-1691-5

Ejemplares similares